COVID-19. Novel Cronavirus Disease (COVID-19)
Conditions
Interventions
Intervention 1: Intervention group: In the intervention group, participants will receive Laris-Hyssop distillate (including hyssop, Echium amoenum, Adiantum capillus-veneris, Hollyhocks, Eucalyptus, M
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: COVID-19 patients aged 15 years and older Newly admitted people (first day of hospitalization) Obtaining informed consent to participate in the trial Non-participation in another clinical trial simultaneously
Exclusion criteria
Exclusion criteria: Epilepsy Having liver or kidney failure according to the patient's statement, and doctor examination or based on creatinine, SGOT, SGPT, LDH tests. Having a chronic disease (cardiovascular disease, uncontrolled high blood pressure (hypertension above 160/100 despite taking medication), complicating diabetes, respiratory diseases, BMI> 40 according to the patient's statement, and doctor examination Immunodeficiency (treated with Corticosteroids over 12.5 mg / d Prednisolone for more than two weeks, chemotherapy, malignancies, organ transplants, HIV patients, other viral diseases) Pregnancy (according to the patient's statement and examination by a doctor) Breastfeeding (according to the patient's statement)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum CRP level. Timepoint: Before-After intervention (14 days). Method of measurement: Biochemical method.;Number of inpatient days. Timepoint: After intervention. Method of measurement: Questionnaire.;Mortality. Timepoint: Daily. Method of measurement: Questionnaire.;Respiratory Rate. Timepoint: Daily. Method of measurement: Observation.;Oxygen saturation (SpO2). Timepoint: Daily. Method of measurement: Pulse Oximeter.;Serum White Blood Cell count. Timepoint: Before- After intervention (14 days). Method of measurement: laboratory cell counter. | — |
Secondary
| Measure | Time frame |
|---|---|
| The time of absence of dry Cough. Timepoint: Daily. Method of measurement: Daily symptom questionnaire.;The time of absence of trembling. Timepoint: Daily. Method of measurement: Daily symptom questionnaire.;The time of absence of sore throat. Timepoint: Daily. Method of measurement: Daily symptom questionnaire.;The time of absence of difficulty breathing or shortness of breath. Timepoint: Daily. Method of measurement: Daily symptom questionnaire.;The time of absence of temperature equal to or grater than 37/8 C. Timepoint: Daily. Method of measurement: Daily symptom questionnaire.;Body temperature. Timepoint: Daily. Method of measurement: Thermometer.;Negative unilateral infiltration. Timepoint: After intervention. Method of measurement: Radiography- CT SCAN.;Negative bilateral infiltration. Timepoint: After intervention. Method of measurement: Radiography- CT SCAN. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJavad Ahmadian heris
Tabriz University of Medical Sciences
Outcome results
None listed